Peking University Shenzhen Hospital Team Shares Interim Evaluation Data from Urine-Based Cervical Cancer Screening Study...
Over 1,000 investment and business matching meetings, MoUs to support healthcare enterprises to go global ...
The summit convenes over 90 influential international healthcare officials, research and medical experts, start-ups, investors...
The NMPA acceptance of Chance Pharma’s first new drug application advances CXG87, an improved budesonide/formoterol dry powder inhalation therapy, toward potential commercialisation in China. ...
The platform’s creation is rooted in nearly a decade of deep collaboration by a cross-disciplinary team...
Both IV iron therapies are originator products already approved in China and included in the National Reimbursement Drug List (NRDL)...
Demonstrating a Favourable Safety Profile, Robust Immunogenicity, and Promising Preliminary Efficacy...
Delivery of three projects highlights growing adoption of AI-driven, scenario-based applications across enterprise and digital services...
CStone presents preclinical data on three differentiated antibody-drug conjugates, including a dual-target EGFR/HER3 candidate...
He played a key role in the development strategy for dapagliflozin, a leading SGLT-2 inhibitor that has become a global blockbuster in the treatment of metabolic diseases...
